Blood test using large oncosomes to profile aggressive prostate cancer
Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood Test
A new blood test will look for large cancer-derived particles in men with advanced prostate cancer to identify molecular subtypes and predict treatment response.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11399213 on NIH RePORTER |
What this research studies
This project uses blood draws to capture large oncosomes, which are cancer-derived extracellular vesicles, and measures proteins and RNA inside them. The team will translate prior lab findings into a CLIA-ready assay and test it on a large set of clinically annotated samples collected both retrospectively and prospectively from two sites. They will perform analytical validation and then see whether oncosome signatures match short or long responses to treatment in both hormone-sensitive and castration-resistant patients. The approach aims to track tumor phenotype over time with minimally invasive blood sampling instead of repeated biopsies.
Who could benefit from this research
Good fit: Men with metastatic or biologically aggressive prostate cancer, including both hormone-sensitive and castration-resistant disease, who can provide blood samples and clinical information.
Not a fit: Men with early-stage, localized prostate cancer or people without prostate cancer are unlikely to receive direct benefit from this assay.
Why it matters
Potential benefit: If successful, the test could help doctors choose treatments and monitor aggressive prostate cancer more easily and without repeated tissue biopsies.
How similar studies have performed: Small pilot cohorts and laboratory studies have shown promising oncosome markers, but translating these findings into a validated clinical blood test in large patient cohorts is still novel.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Di Vizio, Dolores — Cedars-Sinai Medical Center
- Study coordinator: Di Vizio, Dolores
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.